Xeris Biopharma Holdings (XERS) Other financing activities (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Other financing activities of $847000.0 for Q1 2026, down 89.84% on a QoQ basis from $8.3 million in Q3 2025, and down 82.58% year-over-year from $4.9 million in Q1 2025.
Xeris Biopharma Holdings (XERS) Other financing activities (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Other financing activities history runs 7 years deep, the most recent figure standing at $847000.0 for Q1 2026.
- Quarterly Other financing activities fell 82.58% year-over-year to $847000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (up 17.06% YoY) and the FY2025 annual result came in at $9.2 million, changed N/A from the prior year.
- Other financing activities was $847000.0 for Q1 2026 at Xeris Biopharma Holdings, down from $8.3 million in the prior quarter.
- Across five years, Other financing activities topped out at $8.3 million in Q3 2025 and bottomed at -$4.0 million in Q2 2025.
- A 5-year average of $914000.0 and a median of $459000.0 in 2024 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2022 — Other financing activities tumbled 142.51% — and 2025, when it jumped 959.04%.
- Xeris Biopharma Holdings' Other financing activities stood at -$502000.0 in 2022, then decreased by 2.99% to -$517000.0 in 2023, then advanced by 11.22% to -$459000.0 in 2024, then surged by 1916.34% to $8.3 million in 2025, then plunged by 89.84% to $847000.0 in 2026.
- Business Quant data shows XERS's Other financing activities at $847000.0 in Q1 2026, $8.3 million in Q3 2025, and -$4.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 847,000.00 |
| Mar 31, 2026 | 847,000.00 |
| Sep 30, 2025 | 8.34 Mn |
| Sep 30, 2025 | 8.34 Mn |
| Jun 30, 2025 | -4.03 Mn |
| Jun 30, 2025 | -4.03 Mn |
| Mar 31, 2025 | 4.86 Mn |
| Mar 31, 2025 | 4.86 Mn |
| Dec 31, 2024 | -459,000.00 |
| Dec 31, 2024 | -459,000.00 |
| Mar 31, 2024 | 459,000.00 |
| Mar 31, 2024 | 459,000.00 |
| Dec 31, 2023 | -517,000.00 |
| Dec 31, 2023 | -517,000.00 |
| Jun 30, 2023 | 549,000.00 |
| Jun 30, 2023 | 549,000.00 |
| Sep 30, 2022 | -502,000.00 |
| Sep 30, 2022 | -502,000.00 |
| Jun 30, 2022 | 502,000.00 |
| Jun 30, 2022 | 502,000.00 |